Josefina Serrano López

Implications of immunosenescence in the design of NK cell-based antitumor immunotherapy protocols in models of melanoma and acute myeloid leukemia

A phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in patients with acute myeloid leukemia in complete remission

Study for the validation of an ex vivo personalized medicine test in acute lymphoblastic leukemia

Effect of clinical and genetic variables on the optimization of antifungal pharmacotherapy through the use of clinical pharmacokinetics

Maintenance treatment with 5-Azacitidine in patients with acute myeloblastic leukemia who are not eligible for intensive treatment and who have a partial or complete response following induction chemotherapy

Multicenter, prospective, open-label, single-arm, phase I-II clinical trial to evaluate induction therapy with a combination of fludarabine, idarubicin, cytarabine, G-CSF, and plerixafor for the treatment of young patients with relapsed or refractory AML

Multicenter, prospective, open-label, single-arm, phase II clinical trial to evaluate induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine for the treatment of patients aged 60 years or older with AML

I study Th17 cells in the pathogenesis of Graft-versus-Host Disease after allogeneic hematopoietic precursor transplantation

A retrospective multicenter study to describe the effectiveness and safety of clofarabine as a compassionate use treatment in adult patients with relapsed/refractory acute leukemia prior to hematopoietic stem cell transplantation

National Registry of Patients Diagnosed with Acute Myeloid Leukemia According to WHO Criteria and Treated with Azacitidine. ALMA

A multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and the FLAG-IDA chemotherapy regimen in first relapsed/refractory acute myeloid leukemia (R/R AML) patients

PEVOLAM: A randomized phase III, multicentre, open label clinical trial comparing azacitidine plus pevonedistat versus azacitidine in Older/Unfit patients with newly diagnosed acute myeloid leukemia who are ineligible for standard induction chemotherapy

Phase III, multicenter, randomized, open-label study of azacitidine (vidaza(r)) versus fludarabine and cytarabine (fluga regimen) in elderly patients with newly diagnosed acute myeloid leukemia

CC-486-AML-001: Phase 3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

PHASE III, MULTICENTER, RANDOMIZED, OPEN-LAID STUDY OF AZACITIDINE (VIDAZA(r)) VERSUS FLUDARABINE AND CYTARABINE (FLUGA SCHEME) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

TUD-APOLLO-064: A randomized phase III study comparing arsenic trioxide (ATO) combined with ATRA and idarubicin versus standard ATRA- and anthracycline-based chemotherapy (AIDA) in patients with newly diagnosed high-risk acute promyelocytic leukemia

M19-708: Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type AML

AC220-A-U302 Quantum First: A phase 3, double-blind, placebo-controlled study of Quizartinib (AC220) administered in combination with induction and consolidation chemotherapy, and administered as maintenance therapy in subjects 18 to 75 years old with newly diagnosed FLT3-ITD (+) acute myeloid leukemia

PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 04449913, AN ORAL HEDGEHOG PATHWAY INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW-DOSE ARA-C, OR DECITABINE, ADMINISTERED TO PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME

PFIZER COLLABORATION AGREEMENT COMPUTER TOOL FOR THE DEVELOPMENT AND MAINTENANCE OF THE TOOL FOR THE PROCESSING AND ANALYSIS OF DATA FROM THE STUDY VORICONAZOLE ANTIFUNGAL PROPHYLASIS IN PATIENTS WITH NEUTROPENIA